Background
Phase 3, global (298 centres), double-blind, placebo-controlled RCT; N=899; previously untreated, high-intermediate-risk or high-risk (IPI/aaIPI) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL); randomized 1:1, stratified by IPI/aaIPI and region. Rationale: ~40% of high-risk DLBCL are not cured by R-CHOP. Tafasitamab = Fc-enhanced anti-CD19 monoclonal antibody, added with lenalidomide to R-CHOP.
Results
Interventions and follow up: Arm A: Tafasitamab 12 mg/kg IV days 1, 8, 15 + lenalidomide 25 mg PO days 1–10 + standard R-CHOP, six 21-day cycles (n=448)
Arm B: Matching placebos + standard R-CHOP — rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 (max 2 mg) day 1, prednisone/prednisolone 100 mg days 1–5; six 21-day cycles (n=451)
Primary endpoint: Investigator-assessed PFS (ITT)
mFollow up: 35.2 mo
Results: PFS: HR 0.75 (95% CI 0.59–0.96); P=.0194
2-yr PFS: 71.1% vs 62.9%
OS (interim): HR 0.85 (95% CI 0.63–1.14); immature
Deaths (all-cause): 82 (19%) vs 97 (22%)
Arm B: Matching placebos + standard R-CHOP — rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 (max 2 mg) day 1, prednisone/prednisolone 100 mg days 1–5; six 21-day cycles (n=451)
Primary endpoint: Investigator-assessed PFS (ITT)
mFollow up: 35.2 mo
Results: PFS: HR 0.75 (95% CI 0.59–0.96); P=.0194
2-yr PFS: 71.1% vs 62.9%
OS (interim): HR 0.85 (95% CI 0.63–1.14); immature
Deaths (all-cause): 82 (19%) vs 97 (22%)
Adverse events
Grade ≥3 TEAE (any): 87% vs 76%
Fatal TEAE: 6% vs 4%
Discontinuation (all study drugs): 16% vs 15%
Fatal TEAE: 6% vs 4%
Discontinuation (all study drugs): 16% vs 15%
Conclusions
Adding tafasitamab + lenalidomide to R-CHOP significantly improved PFS in newly diagnosed high-risk DLBCL/HGBL (25% reduction in progression/death), with a concordant EFS benefit. OS is immature. The regimen carries higher grade ≥3 and fatal TEAE rates. Potentially the first frontline regimen in years to improve on R-CHOP in high-risk aggressive B-cell lymphoma.
Key Limitations
OS immature (interim HR 0.85, CI crosses 1) — survival impact unproven; PFS HR upper CI near 1 (0.96) with only marginal significance (P=.0194) and a modest ~8-point absolute 2-yr gain; higher fatal-TEAE rate (6% vs 4%) signals a tolerability trade-off; cell-of-origin/molecular subgroups not yet reported; ctDNA/molecular-response analyses pending.
Clinical Context
Tafasitamab (Monjuvi/Minjuvi) is FDA/EMA approved with lenalidomide for relapsed/refractory DLBCL not eligible for ASCT (L-MIND); frontMIND is the registrational frontline study, with a US sBLA for the 1L indication planned for 1H 2026. Prior frontline efforts to beat R-CHOP have been largely negative (POLARIX improved PFS but not OS with pola-R-CHP). NCCN, ASCO, and ESMO currently recommend R-CHOP (or pola-R-CHP) as preferred 1L standards pending regulatory review. Presented at ASCO 2026 with simultaneous Lancet publication.